Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (FC) With a 24-week Open-label Treatment Extension

NCT05652205 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05652205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05652205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (FC) With a 24-week Open-label Treatment Extension
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
December 29, 2022
Completion date
September 2, 2025
Enrollment
123 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

chronic idiopathic constipation (cic), functional constipation (fc)